Item 8.01 Other Events.

On September 22, 2020, Vaccinex, Inc. (the "Company") issued a press release announcing data from the Company's Phase 2 SIGNAL trial evaluating pepinemab for the treatment of Huntington's disease ("HD") in early manifest and late prodromal (pre-manifest) HD patients. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Previously, on September 17, 2020, the Company announced that it had entered into a clinical collaboration agreement with a subsidiary of Merck & Co., Inc. to evaluate pepinemab in combination with anti-PD-1checkpoint inhibitor Keytruda® (pembrolizumab) in a Phase 1/2 clinical trial to treat advanced, recurrent or metastatic head and neck squamous cell carcinoma.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are filed herewith:





          Exhibit Number   Exhibit Description

          99.1               Press Release, dated September 22, 2020




                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses